Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7846 to 7860 of 8914 results

  1. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care (DG56)

    We have moved Diagnostics guidance 56 to become HealthTech guidance 690. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  2. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)

    We have moved Diagnostics guidance 58 to become HealthTech guidance 719. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (DG6)

    We have moved Diagnostics guidance 6 to become HealthTech guidance 292. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  4. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (DG60)

    We have moved Diagnostics guidance 60 to become HealthTech guidance 729. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (DG62)

    We have moved Diagnostics guidance 62 to become HealthTech guidance 735. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  6. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

    We have moved Diagnostics guidance 8 to become HealthTech guidance 315. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (DG61)

    We have moved Diagnostics guidance 61 to become HealthTech guidance 730. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  8. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

    We have moved Diagnostics guidance 9 to become HealthTech guidance 316. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection (DG7)

    This guidance has been updated and replaced by NICE healthtech guidance 598.

    Withdrawn guidance

  10. Endovascular closure of perimembranous ventricular septal defect (IPG172)

    This guidance has been updated and replaced by NICE HealthTech guidance 213.

    Withdrawn guidance

  11. Percutaneous fetal balloon valvuloplasty for pulmonary atresia with intact ventricular septum (IPG176)

    We have moved interventional procedures guidance 176 to become HealthTech guidance 114. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. Percutaneous cementoplasty for palliative treatment of bony malignancies (IPG179)

    We have moved interventional procedures guidance 179 to become HealthTech guidance 117. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  13. Short-term circulatory support with left ventricular assist devices as a bridge to cardiac transplantation or recovery (IPG177)

    We have moved interventional procedures guidance 177 to become HealthTech guidance 115. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer (IPG174)

    We have moved interventional procedures guidance 174 to become HealthTech guidance 113. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  15. Percutaneous laser therapy for fetal tumours (IPG180)

    We have moved interventional procedures guidance 180 to become HealthTech guidance 118. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance